Entities / Company
Argenx.
company in Ghent, Belgium
- Reports this week
- 0
- Active events
- 0
- Connections
- 42
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Earlier this month
-
Wells Fargo and UBS analysts issued bullish predictions regarding Argenx's share price on September 20, 2026.Some support2 reports
-
Several biotech companies reported clinical trial setbacks, including Argenx and Immunovant, while Sling Therapeutics' drug was compared to offerings from Viridian and Amgen.Some support1 report
-
Argenx's CFO commented to Reuters regarding market status, following Vyvgart's approval for use in Japan.Some support1 report
-
Argenx's drug Vyvgart showed promise in treating various inflammatory diseases.Some support2 reports
One to three months ago
-
UBS issued a bullish note on August 26, 2026, which drove up Argenx's stock price.Some support1 report
-
Royalty payments from Roche and J&J for various drugs, alongside Argenx's demand and the acquisition of Antares Pharma's Xyosted, were reported.Some support2 reports1 development inside
-
Argenx announced a definitive agreement to acquire Forte Biosciences.Well supported14 reports
Gone quiet
No new reports in 90+ daysNo events began in the chosen period. Widen it, or reset.
Around Argenx this week
News at the entities that move Argenx most-
UBS OperationalThe Swiss parliament has proposed stricter capital requirements for UBS.Moves Argenx
-
University of Pittsburgh OperationalHeritage Valley Health System and Allegheny Health Network are pursuing strategic integration and competing for surgical talent.Moves Argenx
-
Wells Fargo Mentioned togetherWells Fargo upgraded Sweetgreen stock to overweight from equal weight on September 28, 2026.Moves Argenx
-
Reuters TransactionalAndrii Biletskyi is reporting on military operations, including deploying UGVs and leading the Third Army Corps operations against Russian lines.Moves Argenx
-
Netherlands Shared contextAruba, Curaçao, Sint Maarten, and the Netherlands collaborated on digitizing historical meteorological archives.Moves Argenx
Connections
The 9 strongest of 42, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Forte Transactional
Argenx is acquiring Forte, leading to a merger of Forte into Argenx.
-
Alexandra Roy Structural
Alexandra Roy is employed by Argenx as an investor contact.
-
University of Pittsburgh Operational
The company utilizes the university for ongoing research collaboration.
-
Reuters Transactional
Argenx's CFO provided market status commentary to Reuters.
-
Rohit Aggarwal Operational
Dr Aggarwal functions as an investigator for a Phase III clinical trial associated with Argenx.
-
UBS Operational
UBS issues market notes and predictions that directly influence Argenx's stock price and market perception.
-
Netherlands Shared context
Argenx operates and announces events within the Netherlands.
-
Wells Fargo Mentioned together
Wells Fargo analysts provide market predictions and commentary regarding Argenx's share price.
Show all 9 connections
-
Goldman Sachs International Transactional
Goldman Sachs International acted as the exclusive financial adviser for Argenx regarding an acquisition.
History
Events by the month they beganSeptember 2026
3 events- Wells Fargo and UBS analysts issued bullish predictions regarding Argenx's share price on September 20, 2026.
- Several biotech companies reported clinical trial setbacks, including Argenx and Immunovant, while Sling Therapeutics' drug was compared to offerings from Viridian and Amgen.
- Argenx's CFO commented to Reuters regarding market status, following Vyvgart's approval for use in Japan.
August 2026
2 eventsShow 1 earlier month
June 2026
3 events- Royalty payments from Roche and J&J for various drugs, alongside Argenx's demand and the acquisition of Antares Pharma's Xyosted, were reported.
- Argenx SE formed a strategic alliance with Unnatural Products Inc. and expanded its therapies across several countries.
- Investor interest in the healthcare AI sector is rising, with future viability depending on Phase 3 trial outcomes.